Redx Pharma

R&D update: RXC004 and RXC007 in the spotlight

Lighthouse | 12 October 2021

Share this note

  • Redx Pharma’s virtual R&D event focussed on its two lead wholly owned assets: RXC004, a porcupine inhibitor shortly set to start its first Phase II trial in genetically selected Wnt-ligand driven cancers, and RXC007, a ROCK2 inhibitor that, following promising initial Phase I data, is expected to enter Phase II studies in idiopathic pulmonary fibrosis in 2022. Building on our September 2021 Update which covered these assets, we highlight new or relevant information emerging from the management and key opinion leader presentations from Prof Scott Kopetz (MD Anderson), Prof Gisli Jenkins (Imperial College London), and Prof Toby Maher (Keck Medicine, USC LA).
  • Effective targeting of the Wnt pathway has been a clinical goal in many solid tumours, notably mCRC (metastatic colorectal cancer) where it plays a critical role in aggressive disease. mCRC outcomes remain very poor, with median survival of 30 months and five-year survival of 12%. MSS mCRC has an even worse prognosis, and anti-PD-1 checkpoint inhibitors have not shown any monotherapy efficacy. In Q421 RXC004 will begin a Phase II monotherapy programme in genetically selected MSS mCRC and pancreatic cancers, and in biliary tract cancer. A CPI-combination (nivolumab) arm in MSS mCRC will start in H122. Success here would not simply address a genetically specified tumour population but could help unlock the potential of CPIs in mCRC.
  • RXC007 is a highly specific ROCK2 inhibitor that targets a nodal point in the fibrosis pathways. Historically addressing ROCK without encountering safety issues has proven difficult. Kadmon’s Rezurock (belumosudil) is the first and only approved ROCK2 inhibitor, for cGvHD, which established a regulatory pathway. Early RXC007 Phase I data following a single dose of 2mg through to 40mg has confirmed preclinical pharmacokinetics, with no adverse effects. Although already at the predicted biologically relevant doses, further escalations are continuing. Full Phase I data are expected in H122.
  • The promise of RXC007 will be explored further in a staged Phase II study in idiopathic pulmonary fibrosis (IPF), a progressive lung condition with a poor prognosis despite two approved products. A Phase IIa safety and tolerability study in IPF with and without standard of care (SoC) will start in 2022 and will inform the Phase IIb dose. The 12-month Phase IIb trial will then evaluate RXC007 plus SoC with forced vital capacity (FVC) lung function as a primary endpoint. If successful here, other fibrotic indications could be explored.

Trinity Delta view: This Virtual R&D event provided third-party validation of the quality of Redx Pharma’s medicinal chemistry expertise in solving druggability issues. Both RXC004 and RXC007 target proven biological pathways that have been difficult to safely address. Recent RXC004 Phase I monotherapy results and these initial RXC007 data demonstrate promising safety profiles and attractive dosing profiles. News flow over the next 12-18 months should provide greater visibility on the clinical potential for both programmes. Our rNPV model, based on conservative assumptions, generates a £350.7m valuation (or 128p/share).


12 October 2021

Market Cap£220.2m
Primary exchangeAIM London
Company CodeREDX
Corporate clientYes

Company description

Redx Pharma specialises in the discovery and development of small molecule therapeutics, with an emphasis on oncology and fibrotic diseases. It aims to initially progress them through proof-of-concept studies, before evaluating options for further development and potential value creation.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2021 Trinity Delta Research Limited. All rights reserved.